Phar­ma groups de­cry Covid-19 vac­cine IP waiv­er ahead of Gene­va con­fer­ence

If the World Trade Or­ga­ni­za­tion gets its way, an IP waiv­er deal for Covid-19 vac­cines may be reached as soon as next week. But the crit­ics keep pil­ing up.

A hand­ful of phar­ma ad­vo­ca­cy and lob­by­ing groups — in­clud­ing the In­ter­na­tion­al Fed­er­a­tion of Phar­ma­ceu­ti­cal Man­u­fac­tur­ers and As­so­ci­a­tions and the Wash­ing­ton Coun­cil on In­ter­na­tion­al Trade — de­cried an IP waiv­er deal on Thurs­day, ar­gu­ing that it’s un­nec­es­sary and threat­ens to quash in­no­va­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER